<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>XEOMIN can capitalize on demand for minimally invasive aesthetics, its protein-free formulation, broader facial and therapeutic indications, repeat-use potential, younger consumers, and expansion across Asia, Latin America and Europe.Dublin, Aug. 17, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6236434/xeomin-sales-forecast-market-size-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4j9mz6&amp;utm_campaign=2326565+-+XEOMIN+Sales+Forecast%2c+and+Market+Size+Analysis+-+2034+Now+Published+%e2%80%94+Examines+2020%e2%80%932034+Sales%2c+Pricing%2c+Patents%2c+and+Regulatory+Milestones&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="XEOMIN Sales Forecast and Market Size Analysis - 2034">"XEOMIN Sales Forecast and Market Size Analysis - 2034"</a> has been added to ResearchAndMarkets.com's offering. XEOMIN Sales Forecast and Market Size Analysis Through 2034 Highlights Global Growth Opportunities The "XEOMIN Sales Forecast and Market Size Analysis - 2034" report provides a comprehensive assessment of XEOMIN (incobotulinumtoxinA), including historical performance, current market trends, sales forecasts, competitive positioning and commercial opportunities across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Key Factors Driving XEOMIN Market Growth XEOMIN market growth is supported by the continued expansion of the global botulinum toxin market. One industry estimate valued the market at approximately USD 6.1 billion in 2022 and projected it to reach USD 13.4 billion by 2032, representing a compound annual growth rate of approximately 8.4% from 2023 to 2032. Another estimate forecasts growth from USD 8.6 billion in 2025 to USD 12.2 billion by 2030. Demand is being driven by rising volumes of minimally invasive aesthetic procedures, aging populations, greater awareness of cosmetic treatments and the continued expansion of therapeutic indications. More than 9.2 million botulinum toxin procedures were performed worldwide in 2022, demonstrating sustained demand for established neurotoxin products. XEOMIN's purified formulation remains an important point of differentiation. The product is free from complexing proteins, a characteristic relevant to clinical decision-making, repeat treatment strategies and long-term therapy. Its positioning may support adoption among patients requiring ongoing treatment and in cases where clinicians consider immunogenicity risk when selecting a botulinum neurotoxin. Regulatory expansion in aesthetic indications has also broadened XEOMIN's addressable patient population. The product received authorization for the simultaneous treatment of upper facial lines, including forehead lines, glabellar lines and lateral canthal lines. This expanded labeling strengthens XEOMIN's position within the competitive medical aesthetics market by enabling treatment of multiple upper-face areas during one session. Additional growth opportunities are emerging from younger patient populations seeking aesthetic procedures, increased disposable income and the influence of digital media on treatment awareness. Merz has also expanded XEOMIN's international reach through a presence in more than 90 countries, distribution partnerships and commercial initiatives across Asia, Latin America and other developing aesthetics markets. Therapeutic Applications and Recent Development Beyond aesthetics, XEOMIN is established across several neurological indications, including cervical dystonia, blepharospasm, upper-limb spasticity and chronic sialorrhea. Growth in neurological care, broader diagnosis and treatment rates, and potential indication expansion are expected to support the product's long-term commercial outlook. In January 2026, Merz Therapeutics announced the completion of a regulatory submission for XEOMIN for the treatment of lower- and upper-limb spasticity in children and adolescents aged 2-17 years in the European Union and European Economic Area. If approved, the indication could expand access to XEOMIN for pediatric patients across Europe and strengthen the product's therapeutic market position. XEOMIN Drug and Clinical Overview XEOMIN is a purified botulinum toxin type A product developed by Merz Pharmaceuticals and supplied as a powder for reconstitution and injection into muscles or glands. Its approved uses vary by market and include upper facial lines, chronic sialorrhea, upper-limb spasticity, cervical dystonia and blepharospasm. XEOMIN inhibits acetylcholine release at the neuromuscular junction through cleavage of SNAP-25, producing temporary chemical denervation in the targeted tissue. The product carries a boxed warning concerning the potential distant spread of toxin effects, which may result in serious swallowing or breathing difficulties and generalized weakness. Appropriate precautions are required for patients with pre-existing neuromuscular conditions. Scope of the XEOMIN Market Report The report evaluates XEOMIN across approved indications such as blepharospasm, dystonia, glabellar lines, muscle spasticity and sialorrhea, as well as potential indications including atrial fibrillation, facial wrinkles, migraine, skin aging and alopecia. Coverage includes: <ul><li>XEOMIN sales forecasts and market size estimates through 2034</li><li>Historical and current sales performance across the 7MM</li><li>Mechanism of action, dosage, administration and clinical development</li><li>Regulatory milestones and anticipated commercial timelines</li><li>Clinical trial design, status, interventions and completion dates</li><li>Pricing, reimbursement and regional cost variations</li><li>Patent information, potential generic entry and pricing implications</li><li>Competitive landscape and late-stage emerging therapies</li><li>SWOT analysis, market positioning and analysts' perspectives</li><li>Commercial partnerships, licensing agreements and merger and acquisition activity</li></ul> XEOMIN Competitive Landscape and Revenue Forecast The XEOMIN market analysis examines marketed competitors and pipeline products that may influence future adoption, pricing and market share. It assesses XEOMIN's clinical differentiation, efficacy and safety profile, formulation characteristics, regulatory position and commercial strategy relative to existing and emerging botulinum toxin therapies. The report also provides forecasts for XEOMIN revenue by indication and geography, including potential peak sales, market penetration assumptions and factors affecting prescription growth. Competitive intelligence includes the number of pipeline candidates, expected launch dates, development status and potential impact of late-stage therapies on XEOMIN sales through 2034. Research Methodology The XEOMIN market forecast is developed using internal databases, primary research, secondary research and analysis conducted by industry specialists. Sources include global regulatory authorities, company disclosures, clinical trial registries, trade journals, white papers, medical publications, industry associations, news platforms and subscription databases. Strategic Value of the Report The analysis is designed to support pharmaceutical companies, investors, healthcare organizations and other stakeholders evaluating XEOMIN's commercial potential. Detailed forecasts and competitive assessments help inform portfolio planning, market-entry strategies, pricing decisions, partnership opportunities and investment priorities. By integrating XEOMIN sales forecasts, clinical developments, regulatory activity and competitive intelligence, the report presents a detailed view of the product's outlook across aesthetic and therapeutic applications. It also identifies the principal growth drivers, market barriers and emerging competitors expected to shape XEOMIN's performance in the United States, Europe and Japan through 2034. Key Topics Covered: 1. Report Introduction 2. XEOMIN Overview in approved indications like Blepharospasm, Dystonia, Glabellar lines, Muscle spasticity, Sialorrhoea; as well as potential indications like Atrial fibrillation, Facial wrinkles, Migraine, Skin aging, and Alopecia 2.1. Product Detail 2.2. XEOMIN Clinical Development 2.2.1. XEOMIN Clinical studies 2.2.2. XEOMIN Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. XEOMIN Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging XEOMIN Therapies) 5. XEOMIN Market Assessment 5.1. XEOMIN Market Outlook in approved and potential indications 5.2. 7MM Analysis 5.2.1. XEOMIN Market Size in the 7MM for approved and potential indications 5.3. Country-wise Market Analysis 5.3.1. XEOMIN Market Size in the United States for approved and potential indications 5.3.2. XEOMIN Market Size in Germany for approved and potential indications 5.3.3. XEOMIN Market Size in France for approved and potential indications 5.3.4. XEOMIN Market Size in Italy for approved and potential indications 5.3.5. XEOMIN Market Size in Spain for approved and potential indications 5.3.6. XEOMIN Market Size in the United Kingdom for approved and potential indications 5.3.7. XEOMIN Market Size in Japan for approved and potential indications 6. XEOMIN SWOT Analysis 7. Analysts' Views 8. Appendix 8.1. Bibliography 8.2. Report Methodology 9. Publisher Capabilities 10. Disclaimer 11. About the Publisher 12. Report Purchase Options List of Tables Table 1: XEOMIN, Clinical Trial Description, 2023 Table 2: XEOMIN, General Description Table 3: Competitive Landscape (Marketed Therapies) Table 4: Competitive Landscape (Emerging Therapies) Table 5: XEOMIN's pricing and cost Assumptions Table 6: XEOMIN's Sales Analysis in the 7MM, in USD million (2020-2034) Table 7: XEOMIN Market Size in the US, in USD million (2020-2034) Table 8: XEOMIN Market Size in Germany, in USD million (2020-2034) Table 9: XEOMIN Market Size in France, in USD million (2020-2034) Table 10: XEOMIN Market Size in Italy, in USD million (2020-2034) Table 11: XEOMIN Market Size in Spain, in USD million (2020-2034) Table 12: XEOMIN Market Size in the UK, in USD million (2020-2034) Table 13: XEOMIN Market Size in Japan, in USD million (2020-2034) List of Figures Figure 1: XEOMIN's Sales Analysis in the 7MM, USD million (2020-2034) Figure 2: XEOMIN Market Size in the United States, USD million (2020-2034) Figure 3: XEOMIN Market Size in Germany, USD million (2020-2034) Figure 4: XEOMIN Market Size in France, USD million (2020-2034) Figure 5: XEOMIN Market Size in Italy, USD million (2020-2034) Figure 6: XEOMIN Market Size in Spain, USD million (2020-2034) Figure 7: XEOMIN Market Size in the United Kingdom, USD million (2020-2034) Figure 8: XEOMIN Market Size in Japan, USD million (2020-2034) For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6236434/xeomin-sales-forecast-market-size-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4j9mz6&amp;utm_campaign=2326565+-+XEOMIN+Sales+Forecast%2c+and+Market+Size+Analysis+-+2034+Now+Published+%e2%80%94+Examines+2020%e2%80%932034+Sales%2c+Pricing%2c+Patents%2c+and+Regulatory+Milestones&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/mc3mz6</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/OWJmYWM5OTQtOTVhNC00MTRlLWExY2YtZjM0ZWE3MWJiYWFjLTEwMjY3MzctMjAyNi0wOC0xNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

XEOMIN Sales Forecast, and Market Size Analysis - 2034 Now Published — Examines 2020–2034 Sales, Pricing, Patents, and Regulatory Milestones

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn